Repligen Corp. 10-Q Summary: Quarter Ended September 30, 1999
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 1999, and the six months ended on that date. Repligen Corporation is a biotechnology company developing drugs for autism (secretin), organ transplantation (CTLA4-Ig), and cancer, while also manufacturing products for therapeutic antibody purification (Protein A). The company operates as a single segment.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 1999 | 6 Months Ended Sep 30, 1999 | 6 Months Ended Sep 30, 1998 |
|---|---|---|---|
| Total Revenues | $982,025 | $1,670,192 | $1,354,604 |
| Net Loss | $(804,768) | $(1,227,356) | $(541,937) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.06) | $(0.03) |
| Cash and Equivalents (End of Period) | $10,912,517 | $10,912,517 | |
| Working Capital | $11,687,026 | $11,687,026 | |
| Product Gross Margin | 50% | 40% | 40% |
Note: Working capital calculated as Total Current Assets ($12,205,383) minus Total Current Liabilities ($518,357). No long-term debt is reported on the balance sheet.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29% quarter-over-quarter and 23% year-to-date. Product revenue surged 194% (Q3) and 90% (YTD) due to increased sales of recombinant Protein A. Conversely, R&D revenue dropped 51% (Q3) due to the absence of a licensing payment received in the prior year.
- Expense Increases: Total expenses rose 86% in the quarter and 35% year-to-date. R&D expenses increased 58% (Q3) driven by secretin and CTLA4-Ig development. SG&A expenses jumped 117% (Q3) largely due to a non-cash charge of $188,265 for warrant issuance related to a financial advisory agreement.
- Liquidity Expansion: Cash and cash equivalents increased by $7.66 million to $10.9 million, primarily driven by $8.9 million in net proceeds from a private placement of common stock closed in June 1999.
Outlook, Risks, and Unusual Items
- Guidance: Management believes the $8.9 million raised in the private placement will fund working capital and capital expenditure requirements for the next 24 months. Operating costs are expected to increase in fiscal 2000 as product development expands.
- Legal Proceedings: A lawsuit against Bristol-Myers Squibb regarding inventorship of CTLA4 patents was dismissed without prejudice in July 1999 due to a lack of legal standing. Repligen intends to pursue the correction of inventorship, noting that failure to obtain shared ownership could restrict commercialization of CTLA4-Ig.
- Subsequent Event: In October 1999, Repligen licensed commercialization rights to two diagnostic secretin products from ChiRhoClin Inc., paying $1 million upfront with future milestones contingent on FDA approval.
- Year 2000 Compliance: The company expects full Y2K compliance by the end of 1999 with estimated costs not exceeding $50,000.
Investor Verification Checklist
- Verify the sustainability of the 194% increase in Product Revenue and the specific terms of the Protein A supply agreement with Amersham Pharmacia Biotech.
- Assess the impact of the dismissed lawsuit against Bristol-Myers Squibb on the future commercialization rights of the CTLA4-Ig drug candidate.
- Monitor the progress of the secretin clinical trials for autism and the FDA status of the diagnostic secretin products licensed from ChiRhoClin.
- Confirm the burn rate relative to the $10.9 million cash balance to validate the 24-month runway projection.
- Review the terms of the financial advisory agreement with Paramount Capital, Inc., specifically regarding future fees and warrant dilution.